热门资讯> 正文
诺华宣布基斯卡利第三阶段NATALEE试验的5年结果
2025-10-17 20:33
- 诺华制药(NVS) 0
- 信息服务集团(III) 0
- 纳比特(NA) 0
- After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
- Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1
- Data also show a 29.1% risk reduction in distant disease-free survival, and a positive trend in overall survival*1
- With a median of around two years post-completion of treatment with Kisqali, no new safety signals were observed
推荐文章
华盛早报 | 达成共识！贝森特“不再考虑”对中国加征100%关税，美股三大股指期货齐涨！赛力斯今起招股
一周财经日历 |下周重磅事件抢先看：美联储利率决议、科技巨头财报密集来袭
港股周报 | 利好不断！恒指重回26000点；高息股获资金青睐！农业银行录得12连涨
一周IPO | 八马茶业、滴普科技预计下周二上市；传赛力斯最快下周一招股
美股机会日报 | 9月CPI低于预期！三大股指期货直线拉升；英特尔盘前大涨超5%
营收创新高、利润暴跌29%！马斯克的AI豪赌能撑起特斯拉的未来吗？
甲骨文两日跌超10%，“超预期宏伟目标”不再“吃香”？
小马智行、文远知行回港上市，迎Robotaxi 的deepseek时刻？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
